

Daniel J Klein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11300916/publications.pdf>

Version: 2024-02-01

23
papers

1,648
citations

516710

16
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

1624
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural Basis of glmS Ribozyme Activation by Glucosamine-6-Phosphate. <i>Science</i> , 2006, 313, 1752-1756.	12.6	357
2	The contribution of metal ions to the structural stability of the large ribosomal subunit. <i>Rna</i> , 2004, 10, 1366-1379.	3.5	275
3	Cocrystal structure of a class I preQ1 riboswitch reveals a pseudoknot recognizing an essential hypermodified nucleobase. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 343-344.	8.2	160
4	Riboswitches: small-molecule recognition by gene regulatory RNAs. <i>Current Opinion in Structural Biology</i> , 2007, 17, 273-279.	5.7	140
5	Essential Role of an Active-Site Guanine in <i>glmS</i> Ribozyme Catalysis. <i>Journal of the American Chemical Society</i> , 2007, 129, 14858-14859.	13.7	87
6	Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10062-10097.	6.4	87
7	Requirement of Helix P2.2 and Nucleotide G1 for Positioning the Cleavage Site and Cofactor of the <i>glmS</i> Ribozyme. <i>Journal of Molecular Biology</i> , 2007, 373, 178-189.	4.2	82
8	Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass Spectrometry. <i>ACS Chemical Biology</i> , 2018, 13, 820-831.	3.4	78
9	Insights into activity and inhibition from the crystal structure of human O-GlcNAcase. <i>Nature Chemical Biology</i> , 2017, 13, 613-615.	8.0	75
10	Targeting RNA with Small Molecules: Identification of Selective, RNA-Binding Small Molecules Occupying Drug-Like Chemical Space. <i>SLAS Discovery</i> , 2020, 25, 384-396.	2.7	73
11	Structure of the Bacterial Deacetylase LpxC Bound to the Nucleotide Reaction Product Reveals Mechanisms of Oxyanion Stabilization and Proton Transfer. <i>Journal of Biological Chemistry</i> , 2013, 288, 34073-34080.	3.4	43
12	The <i>glmS</i> Ribozyme Tunes the Catalytically Critical pKa of Its Coenzyme Glucosamine-6-phosphate. <i>Journal of the American Chemical Society</i> , 2011, 133, 14188-14191.	13.7	36
13	Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2476-2483.	2.8	27
14	Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1476-1483.	2.8	21
15	Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127197.	2.2	19
16	Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 4144-4152.	5.4	18
17	Crystallization of the <i>glmS</i> Ribozyme-Riboswitch. <i>Methods in Molecular Biology</i> , 2009, 540, 129-139.	0.9	16
18	Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127367.	2.2	14

#	ARTICLE	IF	CITATIONS
19	Discovery of a Distinct Chemical and Mechanistic Class of Allosteric HIV-1 Integrase Inhibitors with Antiretroviral Activity. ACS Chemical Biology, 2017, 12, 2858-2865.	3.4	13
20	Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction. ACS Medicinal Chemistry Letters, 2021, 12, 540-547.	2.8	9
21	Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity. Journal of Medicinal Chemistry, 2021, 64, 4709-4729.	6.4	7
22	Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128168.	2.2	6
23	Identification of potent inhibitors of the sortilin-progranulin interaction. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127403.	2.2	5